Evidence map›Paper›PMID 42635401›Full record

Trial reportGut microbes2026

Fecal filtrate transplantation as salvage therapy for fulminant

Dorina Korózs, Bálint Gergely Szabó, Gábor Apjok, Viktor Lakatos, Krisztina Jeszenszky, Katalin Kamotsay, Gabriella Hajbel-Vékony, Ákos Tóth, János Sinkó, Péter Reményi and 1 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07172191 (Manipulation of the Enteral Microbiome by Fecal Microbiota Transplantation Among Adult Patients With Malignant Hematological Diseases), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07172191 naenrolling by invitationnot on this map

Manipulation of the Enteral Microbiome by Fecal Microbiota Transplantation Among Adult Patients With Malignant Hematological Diseases

TypeinterventionalSponsorDel-Pest Central Hospital - National Institute of Hematology and Infectious DiseasesRan2025 to 2030Enrolled100ConditionsMalignant Hematologic NeoplasmArmsFecal Microbial Transplantation
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dorina KorózsSemmelweis University, Doctoral School of Clinical Medicine, Budapest, Hungary.
Bálint Gergely SzabóSemmelweis University, Doctoral School of Clinical Medicine, Budapest, Hungary.ORCID 0000-0003-1775-1356
Gábor ApjokHUN-REN Biological Research Centre, National Laboratory of Biotechnology, Institute of Biochemistry, Synthetic and Systems Biology Unit, Szeged, Hungary.
Viktor LakatosSouth Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
Krisztina JeszenszkySemmelweis University, Doctoral School of Clinical Medicine, Budapest, Hungary.
Katalin KamotsaySouth Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
Gabriella Hajbel-VékonyNational Center for Public Health and Pharmacy, Budapest, Hungary.
Ákos TóthNational Center for Public Health and Pharmacy, Budapest, Hungary.
János SinkóSouth Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
Péter ReményiSouth Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
Bálint KintsesHUN-REN Biological Research Centre, National Laboratory of Biotechnology, Institute of Biochemistry, Synthetic and Systems Biology Unit, Szeged, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFulminant

methodsWe conducted a single-center, prospective, protocol-defined pilot case series study including consecutive adults with hematologic malignancies, chemotherapy-induced grade-4 aplasia and fulminant CDI, refractory to ≥5 d of high-dose oral vancomycin plus intravenous metronidazole and tigecycline. FFT was prepared from a single unrelated donor using sequential centrifugation and filtration, and administered via nasogastric tube in two doses. The primary outcome was sustained clinical cure, secondary outcomes included survival and adverse events, assessed at +14 and +30 d post-FFT. 16S rRNA gene sequencing was used to assess microbiome compositions, while viral metagenomics and

resultsThree patients with adverse-risk acute myeloid leukemia and fulminant CDI caused by genetically distinct

conclusionsFFT was feasible, with rapid sustained CDI resolution in hematologic patients with chemotherapy-induced aplasia.

trial registrationClinicalTrials.gov identifier NCT07172191. SUMMARY: Prospective single-center pilot study of fecal filtrate transplantation (FFT) for fulminant-refractory

Indexed as

Clostridioides difficileClostridium InfectionsFecal Microbiota TransplantationHematologic NeoplasmsSalvage TherapyAdultAgedAnti-Bacterial AgentsAntineoplastic AgentsBacteriophagesFecesFemaleHumansMaleMiddle AgedPilot ProjectsAnti-Bacterial AgentsAntineoplastic Agentsaplasiafecal filtratefecal filtrate transplantationfecal microbiota transplantationFMTNeutropeniaphageomestool supernatantstool transplantationvirome

Identifiers

PMID42635401
PMCPMC13523979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.